If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Halozyme ...
Halozyme Therapeutics HALO reported second-quarter 2025 adjusted earnings of $1.54 per share, which comprehensively beat the Zacks Consensus Estimate of $1.23. Earnings rose 69.2% year over year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results